We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MO vs. PM: Which Tobacco Giant Has the Better Growth Story?
Read MoreHide Full Article
Key Takeaways
Philip Morris gets about 42% of quarterly net revenues from smoke-free products across 109 markets.
Altria's cigarette brands held 45.5% U.S. retail share, while domestic cigarette volumes fell 3.2%.
MO leans on U.S. nicotine scale while expanding smoke-free products through Helix and on! PLUS.
Altria Group, Inc. (MO - Free Report) and Philip Morris International Inc. (PM - Free Report) approach the tobacco market from notably different positions, despite sharing roots in traditional nicotine products. Altria is centered on the U.S. market, where its scale in cigarettes and oral tobacco continues to underpin the business. At the same time, the company is investing in newer nicotine formats as changing consumer habits reshape demand across the domestic tobacco landscape.
Philip Morris has built a more geographically diversified business, with smoke-free products accounting for a substantially larger portion of its revenue mix. Its expansion in heated tobacco and oral nicotine has widened the company’s growth avenues and altered its revenue mix. This makes the MO-PM comparison less about two conventional tobacco companies and more about how two different strategies are adapting to the industry’s long-term transition.
Let’s take a closer look at how the two companies stack up.
The Case for Altria Stock
Altria’s market position remains anchored by scale in U.S. nicotine, led by Marlboro and a broad smokeable portfolio. Its cigarette brands held 45.5% retail share in the second quarter of 2026, while Marlboro commanded 59.6% of the premium segment. Smokeable adjusted OCI reached $3 billion, with a 64.8% margin, reinforcing the segment’s importance to earnings.
The company is using a total-portfolio revenue growth management strategy to address different adult nicotine consumer segments. Marlboro remains the premium anchor, Cowboy Cut targets value-sensitive premium smokers and Basic serves discount demand. PM USA supported Basic with targeted promotions in roughly 35,000 stores, using data analytics to refine investments while protecting broader portfolio economics.
Altria is also expanding its smoke-free presence through Helix and on!. The Oral Tobacco Products segment held 29% retail share in the second quarter, while on! PLUS reached about 120,000 stores. Growth efforts include premium retail visibility, trial programs, live events, paid social media, higher nicotine strengths, new flavors and NICOSILK soft-pouch technology.
However, challenges remain concentrated in category decline, consumer pressure and regulatory execution. Domestic cigarette volumes fell 3.2% in the second quarter, while Marlboro’s total-category share declined as discount demand increased. Oral Tobacco Products segment shipment volumes also declined, while illicit e-vapor products remained prevalent. Management continues to emphasize pricing, targeted portfolio investments, smoke-free innovation and enforcement against illicit products.
The Case for Philip Morris Stock
Philip Morris combines global cigarette scale with a rapidly expanding smoke-free franchise. In the second quarter of 2026, its international cigarette category share held at 25.3%, while Marlboro matched a record 11% share. Smoke-free products represented about 42% of quarterly net revenues, highlighting the growing contribution of next-generation products alongside its established combustible tobacco business worldwide.
The company’s strategy centers on a multicategory smoke-free platform led by IQOS, ZYN and VEEV. Smoke-free products were available in 109 markets, while international smoke-free revenues rose 11.8% organically. Growth was supported by IQOS, expanding VEEV adoption and broader ZYN availability, giving PM multiple formats to address evolving preferences among key legal-age nicotine consumers across geographies.
Brand positioning is increasingly supported by portfolio segmentation and product innovation. ZYN held roughly 57% U.S. nicotine-pouch retail value share, while ZYN ULTRA and additional planned strength variants are broadening its ability to address consumer preferences. VEEV became Europe’s leading closed-pod brand and IQOS continued expanding through tiered consumables, new devices and technology-led offerings that deepen engagement with legal-age adult users.
Looking ahead, management expects 2026 adjusted EPS growth of 9.5-11.5%, or 7.5-9.5% excluding favorable currency effects. Philip Morris also projects high-single-digit smoke-free shipment growth. The outlook reflects the company’s strategy of expanding its smoke-free portfolio while leveraging pricing, scale and resilient combustible operations to support earnings growth.
MO vs. PM: How Do the Estimates Stack Up?
The Zacks Consensus Estimate for Altria’s 2026 and 2027 EPS has remained unchanged in the past 30 days at $5.67 and $5.84, respectively. The consensus estimate for MO’s 2026 and 2027 EPS indicates a year-over-year increase of around 4.6% and 3%, respectively.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Philip Morris’ 2026 and 2027 EPS has been revised upward by 5 cents and 6 cents, respectively, over the past 30 days to $8.38 and $9.22. The consensus mark for PM’s 2026 and 2027 EPS implies year-over-year growth of 11.1% and 10%, respectively.
Image Source: Zacks Investment Research
MO & PM: A Look at Past-Year Stock Performance
Over the past year, Altria’s shares have climbed 5.2%, trailing both Philip Morris and the industry, which gained 18.9% and 10.8%, respectively, over the same period.
Image Source: Zacks Investment Research
MO vs. PM: A Peek Into Stock Valuation
Altria is trading at a forward 12-month price-to-earnings (P/E) ratio of 11.92, above its one-year median of 11.80. In comparison, Philip Morris trades at a forward P/E of 21.52, also above its one-year median of 20.15.
Image Source: Zacks Investment Research
MO vs. PM: Which Is the Better Bet Now?
Philip Morris emerges as the stronger growth-oriented name in this comparison, supported by faster projected earnings growth, positive estimate revisions, stronger past-year share performance and an expanding smoke-free portfolio. Altria retains scale and premium leadership in U.S. tobacco, but slower earnings growth and ongoing cigarette-volume pressure temper its momentum. Although PM trades at a richer valuation, its global diversification and accelerating smoke-free transition provide a broader growth platform.
View the Zacks #1 Rank List
Image: Bigstock
MO vs. PM: Which Tobacco Giant Has the Better Growth Story?
Key Takeaways
Altria Group, Inc. (MO - Free Report) and Philip Morris International Inc. (PM - Free Report) approach the tobacco market from notably different positions, despite sharing roots in traditional nicotine products. Altria is centered on the U.S. market, where its scale in cigarettes and oral tobacco continues to underpin the business. At the same time, the company is investing in newer nicotine formats as changing consumer habits reshape demand across the domestic tobacco landscape.
Philip Morris has built a more geographically diversified business, with smoke-free products accounting for a substantially larger portion of its revenue mix. Its expansion in heated tobacco and oral nicotine has widened the company’s growth avenues and altered its revenue mix. This makes the MO-PM comparison less about two conventional tobacco companies and more about how two different strategies are adapting to the industry’s long-term transition.
Let’s take a closer look at how the two companies stack up.
The Case for Altria Stock
Altria’s market position remains anchored by scale in U.S. nicotine, led by Marlboro and a broad smokeable portfolio. Its cigarette brands held 45.5% retail share in the second quarter of 2026, while Marlboro commanded 59.6% of the premium segment. Smokeable adjusted OCI reached $3 billion, with a 64.8% margin, reinforcing the segment’s importance to earnings.
The company is using a total-portfolio revenue growth management strategy to address different adult nicotine consumer segments. Marlboro remains the premium anchor, Cowboy Cut targets value-sensitive premium smokers and Basic serves discount demand. PM USA supported Basic with targeted promotions in roughly 35,000 stores, using data analytics to refine investments while protecting broader portfolio economics.
Altria is also expanding its smoke-free presence through Helix and on!. The Oral Tobacco Products segment held 29% retail share in the second quarter, while on! PLUS reached about 120,000 stores. Growth efforts include premium retail visibility, trial programs, live events, paid social media, higher nicotine strengths, new flavors and NICOSILK soft-pouch technology.
However, challenges remain concentrated in category decline, consumer pressure and regulatory execution. Domestic cigarette volumes fell 3.2% in the second quarter, while Marlboro’s total-category share declined as discount demand increased. Oral Tobacco Products segment shipment volumes also declined, while illicit e-vapor products remained prevalent. Management continues to emphasize pricing, targeted portfolio investments, smoke-free innovation and enforcement against illicit products.
The Case for Philip Morris Stock
Philip Morris combines global cigarette scale with a rapidly expanding smoke-free franchise. In the second quarter of 2026, its international cigarette category share held at 25.3%, while Marlboro matched a record 11% share. Smoke-free products represented about 42% of quarterly net revenues, highlighting the growing contribution of next-generation products alongside its established combustible tobacco business worldwide.
The company’s strategy centers on a multicategory smoke-free platform led by IQOS, ZYN and VEEV. Smoke-free products were available in 109 markets, while international smoke-free revenues rose 11.8% organically. Growth was supported by IQOS, expanding VEEV adoption and broader ZYN availability, giving PM multiple formats to address evolving preferences among key legal-age nicotine consumers across geographies.
Brand positioning is increasingly supported by portfolio segmentation and product innovation. ZYN held roughly 57% U.S. nicotine-pouch retail value share, while ZYN ULTRA and additional planned strength variants are broadening its ability to address consumer preferences. VEEV became Europe’s leading closed-pod brand and IQOS continued expanding through tiered consumables, new devices and technology-led offerings that deepen engagement with legal-age adult users.
Looking ahead, management expects 2026 adjusted EPS growth of 9.5-11.5%, or 7.5-9.5% excluding favorable currency effects. Philip Morris also projects high-single-digit smoke-free shipment growth. The outlook reflects the company’s strategy of expanding its smoke-free portfolio while leveraging pricing, scale and resilient combustible operations to support earnings growth.
MO vs. PM: How Do the Estimates Stack Up?
The Zacks Consensus Estimate for Altria’s 2026 and 2027 EPS has remained unchanged in the past 30 days at $5.67 and $5.84, respectively. The consensus estimate for MO’s 2026 and 2027 EPS indicates a year-over-year increase of around 4.6% and 3%, respectively.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Philip Morris’ 2026 and 2027 EPS has been revised upward by 5 cents and 6 cents, respectively, over the past 30 days to $8.38 and $9.22. The consensus mark for PM’s 2026 and 2027 EPS implies year-over-year growth of 11.1% and 10%, respectively.
Image Source: Zacks Investment Research
MO & PM: A Look at Past-Year Stock Performance
Over the past year, Altria’s shares have climbed 5.2%, trailing both Philip Morris and the industry, which gained 18.9% and 10.8%, respectively, over the same period.
Image Source: Zacks Investment Research
MO vs. PM: A Peek Into Stock Valuation
Altria is trading at a forward 12-month price-to-earnings (P/E) ratio of 11.92, above its one-year median of 11.80. In comparison, Philip Morris trades at a forward P/E of 21.52, also above its one-year median of 20.15.
Image Source: Zacks Investment Research
MO vs. PM: Which Is the Better Bet Now?
Philip Morris emerges as the stronger growth-oriented name in this comparison, supported by faster projected earnings growth, positive estimate revisions, stronger past-year share performance and an expanding smoke-free portfolio. Altria retains scale and premium leadership in U.S. tobacco, but slower earnings growth and ongoing cigarette-volume pressure temper its momentum. Although PM trades at a richer valuation, its global diversification and accelerating smoke-free transition provide a broader growth platform.
PM currently has a Zacks Rank #2 (Buy), while MO carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.